Examples of using Performance status in English and their translations into Danish
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
The majority of patients included had an ECOG performance status of≤ 1.
Age, gender and WHO performance status had no effect on the pharmacokinetics of rituximab.
Three hundred and ninety-six(86%) patients had a baseline ECOG Performance Status of 0 or 1.
Median time to first deterioration of WHO performance status was significantly longer in the TPF arm compared to PF.
Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.”.
The CHMP also deleted the mention of performance status and adopted the following wording.
The ECOG performance status was comparable between both groups, as was the number and type of prior therapies.
If you have labile diabetes or your performance status is severely deteriorated.
Accurate assessment of performance status at the time therapy is given is important,to ensure that patients have not deteriorated to performance status 3.
About two-thirds of the patients were male andapproximately one-third had a baseline ECOG performance status(PS) of 2, and 9% had a baseline ECOG PS of 3.
Sixty-four percent of patients had impaired performance status(ECOG 1 or 2) at study entry; 79% had visceral metastases; and 76% had> 3 sites of metastases.
There are no systematic data available from patients with labile diabetes,from patients with severely altered performance status or from patients with cardiac failure.
The deterioration in Quality of Life and WHO performance status was significantly less in Bondronat treated patients compared with placebo.
Secondary end-points included change of pain, global rating of quality of life by EuroQoL-5D, Lung Cancer Symptom Scale, andchanges in Karnosfky performance status.
Battery in most of the scene is the use of series, the performance status of a single battery directly affects the battery performance status. .
The 5 randomised studies investigated a total of 3734 patients with metastatic colorectal cancer, in whom EGFR expression was detectable and who had an ECOG performance status of≤ 2.
The overall mean age was 59.4 years;56.6% of patients had an ECOG performance status of 0, 43% had a value of 1 and 0.4% had a value of 2.
As expected, patients with poor performance status(PS> 1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis see section 4.8.
The efficacy and safety of lapatinib in combination with capecitabine in breast cancer patients with good performance status was evaluated in a randomized, phase III trial.
Baseline Females Baseline ECOG performance status(PS) 0 Baseline ECOG performance status(PS) 1 Baseline ECOG performance status(PS) 2 Metastatic disease at baseline.
The clinical benefit, as measured by overall survival, was seen in all pre-specified patient subgroups, including those defined by age,sex, performance status, location of primary tumour, number of organs involved and duration of metastatic disease.
The CHMP agreed that gemcitabine used as single agent has shown activity against NSCLC but considered that the combination treatment with gemcitabine+ cisplatin is the first line of treatment in patients with advanced/ metastatic NSCLC and therefore asked the MAH to further justify the indication of Gemzar as combination treatment and as single agent in NSCLC,bearing in mind that single-agent therapy will usually be restricted to patients with a borderline performance status, elderly patients or pretreated patients.
The results from the trial were not consistent in the subgroup of patients with a poor performance status(WHO PS=2, n=70), where overall survival and time to progression were similar in both arms.
The CHMP reviewed the MAH responses and agreed that as a single agent,gemcitabine has a specific role in patients with a borderline performance status and elderly patients and that gemcitabine is an option between other treatments, although no specific agent has been identified to be better than others.
The MAH agreed that platinum-based combination therapies are the standard of care butdefended the use of gemcitabine monotherapy in the treatment of elderly patients and patients with a Performance Status of 2, as these groups are at higher risk for chemotherapy-related morbidities or in cases where platinum-based combinations cannot be tolerated.
Processes running, their status and performance information 3.
A reputation for superior performance filling status.
